Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating women who have stage III or stage IV endometrial cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may kill more tumor cells.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gynecologic Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• Histologically confirmed endometrial cancer including 1 of the following subtypes:

• Clear cell carcinoma

• Serous papillary carcinoma

• Endometrioid adenocarcinoma

• Stage III or IV disease

• Positive adnexa

• Metastases to serosa, bowel mucosa, abdomen

• Positive pelvic or paraaortic nodes

• Positive pelvic washings or vaginal involvement within the radiation port

• Tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry

• Must have had a hysterectomy and bilateral salpingo oophorectomy

• No recurrent disease

• No distant metastases outside of abdominopelvic area, including:

• Parenchymal liver metastases

• Lung metastases

• Positive inguinal lymph nodes

• Positive supraclavicular nodes

• Pleural effusion with malignant cytology

• Performance status - GOG 0-2

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• SGOT and alkaline phosphatase no greater than 3 times ULN

• Creatinine no greater than ULN

• Cardiac ejection fraction greater than 50%

• No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer

• No prior chemotherapy

• No prior pelvic or abdominal radiotherapy

• No prior radiotherapy for other prior malignancy